Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Aug 21, 2011 6:19pm
484 Views
Post# 18965153

Stock swap

Stock swapI was never talking about a hostile takeover, we will see Gen-Probe acquire CUR using their shares and it will be voted in favor by share holders as long as it is over the $3.00 to $4.00 range. Anything under, than it won't happen because the company is much more valuable than that. Even at $160 million we know it is worth more, but regardless, my feeling is that it will be gone. Its been a long road and its evident by the selling this past year. I have been buying because I am looking from this point and a 400% to 500% gain will make a nice Christmas present. Again, I don't want to see it happen because we will see a much higher share price next year. I still think a move above the 52 week high and a push to $1.50 prior to 10/14 is key, we could double after a positive vote and move to $4.00 with FDA approval. It all depends on what we can hold. Fradet should make a run here in the States sometime next year and by than GPRO will have missed the window. 
Bullboard Posts